Osteoarthritis, Knee Clinical Trial
— CORKOfficial title:
Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty - a Randomized, Two by Two Factorial, Double-blind, Placebo-controlled Clinical Trial
The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and/or after surgery. The study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.
Status | Recruiting |
Enrollment | 380 |
Est. completion date | January 2029 |
Est. primary completion date | January 2029 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - Willing and able to read, understand, and sign the informed consent (English) - Willingness to participate in all study measures and restrictions, including patient-reported outcomes and longitudinal follow-up - Scheduled for surgery: primary total knee arthroplasty - Primary diagnosis of osteoarthritis of the surgical knee - Individuals of reproductive potential must agree to use acceptable birth control (defined in manual of operating procedures). This includes currently practicing an effective form of two types of birth control for women of childbearing potential, which are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly from the screening visit until 28 days after the last study drug administration. - Participants must also agree not to donate sperm or eggs during study drug administration - Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen - Agreement to adhere to Lifestyle Considerations (see protocol) throughout study duration Exclusion Criteria: - Revision or bilateral total knee arthroplasty - Individuals receiving or actively applying for worker's compensation or disability and other aspects associated with potential secondary gain - Severe physical impairment or clinically significant illness (e.g., blindness, paraplegia) - Co-morbid medical conditions that may significantly impair physical functional status (e.g., current non-skin malignancies, solid organ transplant in the past year) - Illicit drug use (other than cannabis). Unreported opioid use would be exclusionary but reported prescribed opioid use is allowed (e.g. patient denies opioid use but is found to be positive on the urine drug screen) - Use of cannabis products in the past 30 days (self-report and confirmed with urinalysis). Note - may be rescreened with appropriate wash-out period (see protocol) - High daily preoperative opioid dose - Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain injury/head injury, and seizures - Individuals with significant illness (e.g., cancer) and/or clinically significant labs (e.g. labs measured by complete blood count (CBC) and basic chemistry with values meaningfully outside of the normal range [abnormal levels to be reviewed by the Principal Investigator or prescribing provider]) - Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions) - Pregnant or nursing women (total joint arthroplasty is typically not indicated in this group of patients) - Self-reported liver cirrhosis - Self-reported uncontrolled diabetes - Self-reported active hepatitis (any etiology, including infectious, autoimmune, or alcohol-related) - Blood pressure at screening above 180 millimeters of mercury (mmHg) systolic and/or 120 mmHg diastolic; if value exceeds the set point, potential participants will have repeat assessment within 5 minutes for up to two additional measurements. - Resting heart rate at screening less than 50 beats per minute (bpm) or greater than 100 bpm; if value exceeds the set point, potential participants will have repeat assessment within 5 minutes for up to two additional measurements. - Elevated liver enzymes and bilirubin (measured by blood test at screening) - Serum total bilirubin = 2.5 milligrams (mg) per deciliter (dL) (mg/dL); or, - Alanine transaminase (ALT) or Alanine transaminase (AST) = 3x upper limit normal (ULN); or, - Alkaline phosphatase = 2x ULN - Severe cardiovascular disease (e.g., current unstable angina, current congestive heart failure, or current severe valvular abnormalities) that is self-reported by patient or in medical record - Current valproate, clobazam, or warfarin use per self-report or medical records - Current use of strong inducers of cytochrome p450 (CYP) enzymes CYP3A4 and CYP2C19, or CYP2C19 substrates with a narrow therapeutic index - Self-reported allergies to sesame oil, strawberries, opioids, or cannabis/cannabinoids - Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol - Self-reported severe side effects to opioids precluding the use of opioids for post-surgical pain and/or clear plan not to use any opioids after surgery - Participation in other clinical trials over the course of this study |
Country | Name | City | State |
---|---|---|---|
United States | University of Michigan | Ann Arbor | Michigan |
United States | Henry Ford Health System | Detroit | Michigan |
Lead Sponsor | Collaborator |
---|---|
Chad Brummett | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total postoperative opioid consumption (measured in oral morphine equivalents) during the 28 days after surgery | 28 days (after surgery) | ||
Secondary | The number of treatment-emergent adverse events (TEAEs) | Five weeks of study treatment (Days 1 - 36) | ||
Secondary | Proportion of participants with at least one treatment-emergent adverse events (TEAEs) | Five weeks of study treatment (Days 1 - 36) | ||
Secondary | The Number of serious adverse events (SAEs) | Five weeks of study treatment (Days 1 - 36) | ||
Secondary | Proportion of participants with at least one serious adverse event (SAE) | Five weeks of study treatment (Days 1 - 36) | ||
Secondary | Number of deaths due to any cause | Five weeks of study treatment (Days 1 - 36) | ||
Secondary | Frequency of deaths due to any cause | Five weeks of study treatment (Days 1 - 36) | ||
Secondary | Proportion of participants that prematurely discontinue study medications because of TEAE | Five weeks of study treatment (Days 1 - 36) | ||
Secondary | Percentage of participants that meet or exceed the thresholds of liver enzymes | Protocol eligibility exclusion includes:
Serum total bilirubin = 2.5 milligrams (mg) per deciliter (dL) (mg/dL) Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 3x upper limit normal (ULN) Alkaline phosphatase = 2x ULN |
Five weeks of study treatment (Days 1 - 36) | |
Secondary | Total postoperative opioid consumption (measured in oral morphine equivalents (OME)) during the 28 days after surgery and the pre-operative phase | This is the same outcome as the primary outcome but this secondary endpoint will address the effect of pre-operatively administered CBD and Placebo. | 36 days (pre-post operative) | |
Secondary | Worst pain intensity for surgical site between groups during 7-day epochs from day of surgery through end of active intervention | This is a scale from 0-10 (numerical rating scale, 10 worse pain) in which the participants rate the worse pain. | Days 8-36 (post-surgery) | |
Secondary | Anxiety based on the Patient-Reported Outcomes Measurement Information System (PROMIS)-29+2 profile v2.1 | There are 4-questions on this survey regarding anxiety. Participants answer the questions from never (1) to always (5). Scores range from 4-20 with a higher score indicating higher levels of anxiety. | pre-op days 1-7 | |
Secondary | Anxiety based on the Patient-Reported Outcomes Measurement Information System (PROMIS)-29+2 profile v2.1 | There are 4-questions on this survey regarding anxiety. Participants answer the questions from never (1) to always (5). Scores range from 4-20 with a higher score indicating higher levels of anxiety. | post-op days 8-36 | |
Secondary | Sleep disturbance on the PROMIS-29+2 v.2.1 | There are 4-questions on this survey regarding sleep disturbance with a likert type scale.
Scores range from 4-20 with a higher score indicating higher levels of sleep disturbance. |
pre-op days 1-7 | |
Secondary | Sleep disturbance on the PROMIS-29+2 v.2.1 | There are 4-questions on this survey regarding sleep disturbance with a likert type scale.
Scores range from 4-20 with a higher score indicating higher levels of sleep disturbance. |
post-op days 8-36 | |
Secondary | Change in Interleukin-6 (IL-6) levels in the blood (University of michigan site only) | Baseline, up to day 36 (post -surgery) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03895489 -
Effectiveness of the Journey Total Knee Arthroplasty Versus Two Standard of Care Total Knee Arthroplasty Prostheses
|
N/A | |
Completed |
NCT03660943 -
A Clinical Study to Test Efficacy and Safety of Repeat Doses of CNTX-4975-05 in Patients With Osteoarthritis Knee Pain
|
Phase 3 | |
Completed |
NCT04531969 -
Comparison of Outpatient and Inpatient Spa Therapy
|
N/A | |
Completed |
NCT02848027 -
Correlating the Osteoarthritic Knee Microenvironment to Clinical Outcome After Treatment With Regenexx®SD Treatment
|
Phase 3 | |
Completed |
NCT05160246 -
The Instant Effect of Kinesiology Taping in Patients With Knee OA
|
N/A | |
Recruiting |
NCT06080763 -
Biomechanics and Clinical Outcomes in Responders and Non-Responders
|
||
Completed |
NCT03643588 -
The Comparison of HYAJOINT Plus and Hyalgan Hyaluronan Supplement for Knee Osteoarthritis Pain
|
N/A | |
Active, not recruiting |
NCT05100225 -
Efficacy and Safety Trial of PTP-001 (MOTYS) for Symptomatic Knee Osteoarthritis
|
Phase 2 | |
Active, not recruiting |
NCT04061733 -
New Hydroxyethyl Cellulose Hydrogel for the Treatment of the Pain of Knee Arthrosis
|
N/A | |
Completed |
NCT04051489 -
A Novel Smartphone Application for "Smart" Knee Osteoarthritis Trials
|
||
Recruiting |
NCT05546541 -
Epidemiology and Nutrition
|
||
Recruiting |
NCT05447767 -
Prediction AlgoriThm for regeneraTive Medicine Approach in knEe OA: New Decision-making Process Based on Patient pRofiliNg
|
Phase 2 | |
Not yet recruiting |
NCT04448106 -
Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis
|
Phase 2 | |
Not yet recruiting |
NCT03225911 -
Effect of a Lateral Wedge Insole and Simple Knee Sleeve in Individuals With Knee Osteoarthritis
|
N/A | |
Completed |
NCT05070871 -
A Clinical Trial Investigating the Effect of Salmon Bone Meal on Osteoarthritis Among Men and Women
|
N/A | |
Completed |
NCT05703087 -
Positive Cueing in Knee Arthroplasty.
|
N/A | |
Not yet recruiting |
NCT06042426 -
Effects of Perioperative Intravenous Dexamethasone in Clinical Outcomes After Total Knee Arthroplasty in a Hispanic Population
|
Phase 4 | |
Completed |
NCT03037489 -
A Study to Evaluate Safety and Tolerability of MIV-711 in Osteoarthritis Patients
|
Phase 2 | |
Not yet recruiting |
NCT02826850 -
Saphenous Nerve Radiofrequency for Knee Osteoarthritis Trial
|
Phase 3 | |
Completed |
NCT02905747 -
The Effect of Medical Exercise Therapy on Pain, Function and Physical Activity in Patients With Knee Osteoarthritis
|
N/A |